Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Chem. 2012 Sep;4(9):705-10. doi: 10.1038/nchem.1395. Epub 2012 Jul 15.

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.

Author information

  • 1Department of Chemistry, Stanford University, Stanford, California 94305, USA.

Abstract

Bryostatin is a unique lead in the development of potentially transformative therapies for cancer, Alzheimer's disease and the eradication of HIV/AIDS. However, the clinical use of bryostatin has been hampered by its limited supply, difficulties in accessing clinically relevant derivatives, and side effects. Here, we address these problems through the step-economical syntheses of seven members of a new family of designed bryostatin analogues using a highly convergent Prins-macrocyclization strategy. We also demonstrate for the first time that such analogues effectively induce latent HIV activation in vitro with potencies similar to or better than bryostatin. Significantly, these analogues are up to 1,000-fold more potent in inducing latent HIV expression than prostratin, the current clinical candidate for latent virus induction. This study provides the first demonstration that designed, synthetically accessible bryostatin analogues could serve as superior candidates for the eradication of HIV/AIDS through induction of latent viral reservoirs in conjunction with current antiretroviral therapy.

Comment in

PMID:
22914190
[PubMed - indexed for MEDLINE]
PMCID:
PMC3428736
Free PMC Article

Images from this publication.See all images (3)Free text

Figure 1
Figure 2
Figure 3

Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

Publication Types

MeSH Terms

Substances

Secondary Source ID

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk